These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1072 related articles for article (PubMed ID: 7773209)

  • 1. Interleukin-2 activation of chemotherapy and growth factor-mobilized peripheral blood stem cells for generation of cytotoxic effectors.
    Verma UN; Areman E; Dickerson SA; Kotula PL; Sacher R; Mazumder A
    Bone Marrow Transplant; 1995 Feb; 15(2):199-206. PubMed ID: 7773209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro generation of cytotoxic effectors activated by interleukin 2 (IL-2): comparison of autologous peripheral blood stem cells (PBSC) from adults and children.
    Valteau-Couanet D; Angevin E; Leboulaire C; Beaussier PS; Bayle C; Hartmann O; Beaujean F
    Bone Marrow Transplant; 2001 Apr; 27(8):869-75. PubMed ID: 11477446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the in vivo priming regimen for peripheral blood stem cells (PBSC) mobilization on in vitro generation of cytotoxic effectors by IL-2 activation of PBSC in a murine model.
    Verma UN; Yankelevich B; Hodgson J; Mazumder A
    Bone Marrow Transplant; 1997 Feb; 19(3):265-73. PubMed ID: 9028557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
    Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion.
    Silva MR; Parreira A; Ascensão JL
    Exp Hematol; 1995 Dec; 23(14):1676-81. PubMed ID: 8542964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor.
    Triozzi PL; Tucker F; Benzies T; Balcerzak SP
    Bone Marrow Transplant; 1996 Jul; 18(1):47-52. PubMed ID: 8831995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limiting dilution analysis of the frequency of human T cells and large granular lymphocytes proliferating in response to interleukin 2. I. The effect of lectin on the proliferative frequency and cytotoxic activity of cultured lymphoid cells.
    Vose BM; Bonnard GD
    J Immunol; 1983 Feb; 130(2):687-93. PubMed ID: 6600251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-2 activation of human bone marrow in long-term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors.
    Verma UN; Bagg A; Brown E; Mazumder A
    Bone Marrow Transplant; 1994 Feb; 13(2):115-23. PubMed ID: 8205079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.
    Gehling UM; Ryder JW; Hogan CJ; Hami L; McNiece I; Franklin W; Williams S; Helm K; King J; Shpall EJ
    Exp Hematol; 1997 Oct; 25(11):1125-39. PubMed ID: 9328449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts.
    Klingemann HG; Deal H; Reid D; Eaves CJ
    Exp Hematol; 1993 Aug; 21(9):1263-70. PubMed ID: 8330650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates.
    Meehan KR; Verma UN; Cahill R; Frankel S; Areman EM; Sacher RA; Foelber R; Rajagopal C; Gehan EA; Lippman ME; Mazumder A
    Bone Marrow Transplant; 1997 Oct; 20(8):643-51. PubMed ID: 9383227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
    Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
    Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12.
    Wong EK; Eaves C; Klingemann HG
    Bone Marrow Transplant; 1996 Jul; 18(1):63-71. PubMed ID: 8831997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel approach to immunomodulation of frozen human bone marrow with interleukin-2 for clinical application.
    Charak BS; Areman EM; Dickerson SA; Choudhary GD; Sacher R; Kotula PL; Brown EG; Mazumdar A
    Bone Marrow Transplant; 1993 Feb; 11(2):147-54. PubMed ID: 8435664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological characterization of CD34+ cells mobilized into peripheral blood.
    Lemoli RM; Tafuri A; Fortuna A; Catani L; Rondelli D; Ratta M; Tura S
    Bone Marrow Transplant; 1998 Dec; 22 Suppl 5():S47-50. PubMed ID: 9989890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo cytokine activation of peripheral blood stem cells: a potential role for adoptive cellular immunotherapy.
    Meehan KR; Wu A; Hassan R; Miao Y; Chawla J; Slack R; Gehan E; Herscowitz HB
    J Hematother Stem Cell Res; 2001 Apr; 10(2):283-90. PubMed ID: 11359675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation.
    Neubauer MA; Benyunes MC; Thompson JA; Bensinger WI; Lindgren CG; Buckner CD; Fefer A
    Bone Marrow Transplant; 1994 Mar; 13(3):311-6. PubMed ID: 7911048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
    Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.